Syros Pharmaceuticals Inc... (SYRS)
0.08
-0.06 (-44.13%)
At close: Mar 03, 2025, 3:59 PM
0.08
1.96%
After-hours: Mar 03, 2025, 07:58 PM EST
No 1D chart data available
| Bid | 0.08 |
| Market Cap | 2.19M |
| Revenue (ttm) | 263.75K |
| Net Income (ttm) | -66.84M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | -0.06 |
| Analyst | Hold |
| Ask | 0.09 |
| Volume | 17,978,573 |
| Avg. Volume (20D) | 2,013,996 |
| Open | 0.07 |
| Previous Close | 0.14 |
| Day's Range | 0.07 - 0.09 |
| 52-Week Range | 0.07 - 7.90 |
| Beta | 1.31 |
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2016
Employees 68
Stock Exchange NASDAQ
Ticker Symbol SYRS
Website https://www.syros.com
Analyst Forecast
According to 5 analyst ratings, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 3576.47% from the latest price.
Buy 20.00%
Hold 80.00%
Sell 0.00%
Next Earnings Release
Syros Pharmaceuticals Inc. is scheduled to release its earnings on Mar 26, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
-42.74%
Syros Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
3 months ago
+39.24%
Syros Pharmaceuticals shares are trading higher after falling on Monday after the company announced it gave notice to QIAGEN Manchester of its election to terminate the Master Collaboration Agreement.
